Literature DB >> 20144312

The personalized medicine for diabetes meeting summary report.

David C Klonoff1.   

Abstract

Personalized medicine for diabetes is a potential method to specifically identify people who are at high risk of developing type 2 diabetes based on a combination of personal history, family history, physical examination, circulating biomarkers, and genome. High-risk individuals can then be referred to lifestyle programs for risk reduction and disease prevention. Using a personalized medicine approach, a patient with already-diagnosed type 2 diabetes can be treated individually based on information specific to that individual. The field of personalized medicine for diabetes is rapidly exploding. Diabetes Technology Society convened the Personalized Medicine for Diabetes (PMFD) Meeting March 19-20, 2009 in San Francisco. The meeting was funded through a contract from the US Air Force. Diabetes experts from the military, government, academic, and industry communities participated. The purpose was to reach a consensus about PMFD in type 2 diabetes to (a) establish screening programs, (b) diagnose cases at an early stage, and (c) monitor and treat the disease with specific measures. The group defined what a PMFD program should encompass, what the benefits and drawbacks of such a PMFD program would be, and how to overcome barriers. The group reached six conclusions related to the power of PMFD to improve care of type 2 diabetes by resulting in (1) better prediction, (2) better prophylactic interventions, (3) better treatments, and (4) decreased cardiovascular disease burden. Additional research is needed to demonstrate the benefits of this approach. The US Air Force is well positioned to conduct research and develop clinical programs in PMFD. Copyright 2009 Diabetes Technology Society.

Entities:  

Mesh:

Year:  2009        PMID: 20144312      PMCID: PMC2769958          DOI: 10.1177/193229680900300410

Source DB:  PubMed          Journal:  J Diabetes Sci Technol        ISSN: 1932-2968


  18 in total

1.  Personalized medicine for diabetes.

Authors:  David C Klonoff
Journal:  J Diabetes Sci Technol       Date:  2008-05

2.  A strategy for analyzing gene-nutrient interactions in type 2 diabetes.

Authors:  Carolyn Wise; Jim Kaput
Journal:  J Diabetes Sci Technol       Date:  2009-07-01

3.  Pharmacogenetics for type 2 diabetes: practical considerations for study design.

Authors:  Adrian Vella
Journal:  J Diabetes Sci Technol       Date:  2009-07-01

Review 4.  Genetic susceptibility to type 2 diabetes and implications for therapy.

Authors:  Jose C Florez
Journal:  J Diabetes Sci Technol       Date:  2009-07-01

Review 5.  Environmental influences on development of type 2 diabetes and obesity: challenges in personalizing prevention and management.

Authors:  Abby G Ershow
Journal:  J Diabetes Sci Technol       Date:  2009-07-01

Review 6.  The case for personalized medicine.

Authors:  Edward Abrahams; Mike Silver
Journal:  J Diabetes Sci Technol       Date:  2009-07-01

Review 7.  Ethical issues of predictive genetic testing for diabetes.

Authors:  Susanne B Haga
Journal:  J Diabetes Sci Technol       Date:  2009-07-01

8.  Noninvasive optical screening for diabetes.

Authors:  Marwood N Ediger; Byron P Olson; John D Maynard
Journal:  J Diabetes Sci Technol       Date:  2009-07-01

Review 9.  The prevention of type 2 diabetes: an overview.

Authors:  David G Marrero
Journal:  J Diabetes Sci Technol       Date:  2009-07-01

Review 10.  Waist circumference threshold values for type 2 diabetes risk.

Authors:  Karl E Friedl
Journal:  J Diabetes Sci Technol       Date:  2009-07-01
View more
  2 in total

Review 1.  Neural vulnerability factors for obesity.

Authors:  Eric Stice; Kyle Burger
Journal:  Clin Psychol Rev       Date:  2018-12-19

Review 2.  Asynchronous and synchronous teleconsultation for diabetes care: a systematic literature review.

Authors:  Fenne Verhoeven; Karin Tanja-Dijkstra; Nicol Nijland; Gunther Eysenbach; Lisette van Gemert-Pijnen
Journal:  J Diabetes Sci Technol       Date:  2010-05-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.